Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could everyday supplements ease a rare lung disease?

NCT ID NCT06567717

Recruiting now Symptom relief Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of zinc and nicotinamide riboside can help people with idiopathic pulmonary fibrosis (IPF) feel better and breathe easier. Sixty participants will take the supplements or a placebo twice a day for 24 weeks, all from home with remote check-ins. The main goal is to see if this home-based approach works for future trials, while also checking for any symptom improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zinc and nicotinamide riboside
What this could lead to
If it works, this could point toward a simple supplement-based way to improve symptoms and quality of life for people with IPF.
What could go wrong
This is a small, early-phase trial focused on feasibility, not yet on proving effectiveness. The supplements may not improve lung function or symptoms, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic interstitial pneumonia idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Cedars-Sinai

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.